// COMPANY
AnaCardio
SECTOR BIOTECHMENTIONS 1LAST SEEN OCTOBER 2, 2026
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
funding·StrictlyVC·OCTOBER 2, 2026
“AnaCardio, a Stockholm drug developer for advanced heart failure that develops an oral drug designed to strengthen heart contractions, raised a $70.9M Series B.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.